SCHEMBL23792704

SCHEMBL23792704

CC(C)c1sc(NCC(CCc2ccccc2)C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 2/20 0.40
▸ RORC P51449 1/20 0.39
▸ IGF2BP2 Q9Y6M1 1/20 0.39
▸ FDFT1 P37268 1/20 0.38
▸ TEAD2 Q15562 2/20 0.37
▸ DHODH Q02127 1/20 0.36
▸ MME P08473 1/20 0.36
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ RXRG P48443 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35
▸ KMO O15229 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23782610 0.91 MEN1 (0.43) PTGDR2RORCFDFT1TEAD2DHODH
SCHEMBL30173803 0.91 MEN1 (0.43) PTGDR2RORCFDFT1TEAD2DHODH
SCHEMBL23792227 0.90 PTGDR2 (0.51) PTGDR2RORCDHODHMEN1KMT2A
SCHEMBL23792708 0.87 PTGDR2 (0.45) PTGDR2IGF2BP2FDFT1TEAD2DHODH
SCHEMBL23792693 0.85 FDFT1 (0.39) PTGDR2RORCFDFT1DHODHMEN1
SCHEMBL30176185 0.84 DHODH (0.39) PTGDR2RORCFDFT1DHODHRXRA
SCHEMBL23782522 0.84 DHODH (0.39) PTGDR2RORCFDFT1DHODHRXRA
SCHEMBL23792701 0.84 FDPS (0.40) RORCFDFT1MEN1KMT2AKMO
SCHEMBL23792471 0.84 TP53 (0.41) PTGDR2RORCDHODHMEN1KMT2A
SCHEMBL23792721 0.84 PTGDR2 (0.39) PTGDR2IGF2BP2TEAD2MMERXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PTGDR2 4804/4885RORC 3129/4885IGF2BP2 255/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 PTGDR2 4804/4885RORC 3129/4885IGF2BP2 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback